Last updated: 2026-09-16 10:32:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Exagen Inc. (XGN) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $7,50, with a market capitalisation of $178,06M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,59 to $12,23. This page covers its latest market performance, valuation, price trends and company information.
$178,06M | |
$7,32 | |
$29,86 | |
$1,30 | |
$7,35 | |
199,06K | |
310,60K | |
-- | |
$12,23 | |
$2,59 | |
-- | |
-- |
Exagen Inc. (XGN) is trading at $7,33 in pre-market trading as of 2026-09-15 23:31:00, down 0,34% ($0,02) from the previous close of $7,35
Pre-market trading shows how investors are pricing XGN before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Exagen Inc. (XGN) moved from $7,58 to $7,50, representing a decline of 1,07% ($0,08).
The stock traded between $6,83 and $7,70 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 218,24 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 50,9%
XGN is currently trading at $7,50, placing it 50,9% of the way from its 52-week low of $2,59 to its 52-week high of $12,23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 220 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Exagen Inc. (XGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.